Fig. 1 · Structure

Documents & Downloads

Bafetinib (INNO-406)

Cat. No. A10119 CAS 859212-16-1

Bcr-Abl inhibitor

Bafetinib ((INNO-406) is a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.

In Stock

Publications for Bafetinib

5 publications citing this product

  1. Yusuke Kimata, .et al. , Life Sci Alliance, 2023, Feb 27;6(5):e202201657 PMID: 36849250
  2. Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
  3. S. Dallari, .et al. , Nat Commun, 2017, 8: 14830 PMID: 28368000
  4. Andrea Haerzschel, .et al. , Ann Hematol, 2016, 95(12): 1979-1988 PMID: 27542958
  5. Magdalena Winiarska, .et al. , MAbs., 2014, 6(5): 1300-1313 PMID: 25517315

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Abl (Cell-free assay) 5.8 nM
Lyn (Cell-free assay) 19 nM

Bafetinib (INNO-406) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Bafetinib (INNO-406) from 3 published references. In vitro models include Raji human B-cell lymphoma cells; A375-derived SB01-VR melanoma reporter cells.

Bafetinib (INNO-406) In Vitro Studies

In Raji lymphoma cells, 48-hour bafetinib pretreatment reduced surface CD20 antibody-binding signal and impaired subsequent rituximab- and ofatumumab-mediated complement-dependent cytotoxicity. This cell-based finding highlights a potential antagonistic interaction with anti-CD20 treatment. [1]

Bafetinib (5 μM, 30 minutes) attenuated B-cell receptor-triggered calcium mobilization and strongly reduced, but did not completely abolish, chemokine-triggered responses in patient-derived CLL cells. Responses varied among samples. [2]

In A375-derived SB01-VR melanoma cells, bafetinib plus trametinib reduced long-term viability signal and colony growth, with reduced ERK1/2 phosphorylation. At the tested 0.1–0.3 μM concentrations, bafetinib alone did not reduce the displayed 14-day viability signal below the DMSO reference. [3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Bafetinib pretreatment reduces CD20 signal and impairs antibody-mediated CDC

Cell-based study · Raji human B-cell lymphoma cells [1]

One integrated pretreatment experiment links lower surface CD20 signal with reduced complement-dependent cytotoxicity (CDC) after rituximab or ofatumumab. The bafetinib panels are Fig. 2A–C; NK-cell and animal findings in this paper involve other inhibitors and are not attributed to bafetinib.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Surface CD20 antibody-binding signal in viable Raji cellsCD20 MFI relative to control Decreased with increasing bafetinib concentration (qualitative; no curve-derived percentages).[1]
Rituximab- and ofatumumab-mediated complement-dependent cytotoxicity after inhibitor washoutCell survival relative to no-antibody control Bafetinib pretreatment increased survival in CDC assays; impairment was greater for rituximab than for ofatumumab in the displayed comparisons (qualitative).[1]

Literature-Reported Treatment Conditions

Treatment concentration
500, 1000 or 5000 nM bafetinib; zero-inhibitor reference.
Exposure duration
48 h pretreatment; after washing, 1 h CDC assay.
Method
Surface staining/flow cytometry and antibody-plus-serum CDC assay.
Vehicle
DMSO stock solvent (Reagents); solvent matching of zero-inhibitor reference is not explicitly stated in Fig. 2.
Co-treatment
Sequential bafetinib pretreatment followed by rituximab or ofatumumab (1–100 μg/ml) with 10% human AB serum; not a simultaneous in vivo combination.
Reported limits
Within-experiment replicate number is not given in the selected caption. Fig. S2 toxicity controls were not retrieved; no independent non-toxic-concentration claim is made.
Methods and source locations

Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib

Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.

Fig. 2A–C and caption; Results: Inhibitors of SRC family kinases downregulate CD20 levels and impair antitumor activity of anti-CD20 mAbs in Raji cells; Methods: Reagents, Cytotoxicity assay, Staining of surface antigens

Surface CD20 antibody-binding signal in viable Raji cells: Flow cytometry with FITC anti-CD20 clone L27; PI-negative cells; Fig. 2A. — Fig. 2A, middle panel; caption; Staining of surface antigens

Rituximab- and ofatumumab-mediated complement-dependent cytotoxicity after inhibitor washout: After 48 h pretreatment, cells were washed and exposed for 1 h to 1–100 μg/ml antibody plus 10% human AB serum; viability measured with PI. — Fig. 2B–C, middle panels and caption

Bafetinib suppresses BCR- and chemokine-triggered calcium responses

Cell-based study · Ex vivo peripheral-blood CLL samples; included samples had >85% CD19-positive cells. Fig. 6 caption n = 11; Results narrative says ten patients. [2]

At 5 μM, bafetinib reduced BCR-triggered calcium release and strongly diminished responses to CXCL13, CCL21 and CCL19 relative to equal-volume DMSO. Residual and exceptional responses remained. This functional endpoint does not establish an isolated Lyn biochemical IC50 or clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Stimulus-evoked intracellular calcium mobilizationPeak fluorescence minus baseline BCR calcium responses markedly reduced in most samples; responses to all three chemokines strongly reduced but not completely abolished.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM bafetinib.
Exposure duration
30 min inhibitor incubation; calcium signal recorded for 2 min after stimulus.
Method
Fluo-3-AM calcium mobilization by flow cytometry; peak fluorescence minus pre-stimulation baseline.
Vehicle
Equal volume DMSO control.
Co-treatment
Bafetinib tested separately from ibrutinib and R406; receptor agonists are assay stimuli.
Reported limits
Patient number differs between narrative (ten) and Fig. 6 caption (n = 11); unresolved. Exact per-sample values and vehicle percentage not extracted.
Methods and source locations

Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib

Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.

Fig. 6 and caption; Results: Inhibition of Syk, Lyn, and Btk strongly reduces chemokine-induced calcium responses; Methods: Patient samples and cell isolation, Reagents, Intracellular calcium measurement

Stimulus-evoked intracellular calcium mobilization: Fluo-3-AM flow cytometry; after 30 min inhibitor exposure, record baseline and stimulus response; compare equal-volume DMSO. IgM/IgD F(ab′)2 10 μg/ml, CXCL13 500 ng/ml, CCL21/CCL19 200 ng/ml. — Fig. 6 and caption; final Results subsection; Intracellular calcium measurement

Bafetinib plus trametinib in melanoma cells with acquired vemurafenib resistance

Cell-based study · A375-derived SB01-VR melanoma reporter cells [3]

Combination treatment lowered the 14-day viability signal and colony growth more than either drug alone, with reduced ERK1/2 phosphorylation in the 24 h immunoblot. Bafetinib alone at 0.1 or 0.3 μM did not lower the displayed long-term viability signal below the DMSO reference. The experiments do not establish direct ERK binding or formal pharmacological synergy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
14-day viable-cell-associated luminescencePercent labels printed in Fig. 6a DMSO 100% reference; bafetinib 0.1 μM: 118%; bafetinib 0.3 μM: 115%; trametinib 0.0003 μM: 52%; trametinib 0.001 μM: 43%; combinations (bafetinib/trametinib, μM): 0.1/0.0003: 32%, 0.1/0.001: 12%, 0.3/0.0003: 12%, 0.3/0.001: 4%.[3]
ERK1/2 phosphorylation and colony formation under combination treatmentQualitative immunoblot and colony endpoints Combination reduced pERK1/2 and colony growth relative to single agents in this model.[3]

Literature-Reported Treatment Conditions

Treatment concentration
Fig. 6a: bafetinib 0.1 or 0.3 μM; trametinib 0.0003 or 0.001 μM. Fig. 6c uses 0.3 μM bafetinib with the two trametinib concentrations.
Exposure duration
14 days for viability/colonies; 24 h for immunoblot. Medium and drugs replaced after 7 days for long-term assays.
Method
Long-term CellTiter-Glo, colony formation and pERK1/2 immunoblot.
Vehicle
0.5% DMSO for colony assays per Methods; Fig. 6a uses DMSO control without an explicit percentage in its caption.
Co-treatment
Bafetinib plus trametinib, with both single agents and DMSO comparators.
Reported limits
Replicate number and error-bar definition are not specified in the Fig. 6 caption. No direct ERK enzyme inhibition or formal synergy analysis adopted.
Methods and source locations

Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib

Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.

Fig. 6a–c and caption; Results: Identification of a potential novel drug combination to address BRAF resistant melanoma; Methods: Colony and Cell Proliferation Assays, Western Blot, compound list in Gaussia Luciferase Assay

14-day viable-cell-associated luminescence: CellTiter-Glo viability assay per caption; labels transcribed from viewed figure, not calculated from bar heights. Displayed error-bar definition/replicate n not specified in Fig. 6 caption. — Fig. 6a and caption; Colony and Cell Proliferation Assays

ERK1/2 phosphorylation and colony formation under combination treatment: 24 h immunoblot includes total ERK1/2 and actin controls (Fig. 6b); 14-day colony staining with DMSO and single-agent controls (Fig. 6c). — Fig. 6b–c and caption; Western Blot; Colony and Cell Proliferation Assays

Bafetinib (INNO-406) In Vivo Studies

In SB01-VR melanoma xenografts, oral bafetinib plus trametinib reduced tumor growth versus vehicle during the reported days 7–16 interval; neither single agent did so significantly. The 21-day study used unblinded treatment groups, and some control- and trametinib-treated mice were euthanized early because of ulcerations. [3]

Bafetinib–trametinib combination versus single agents in melanoma xenografts

Animal study · Female Nu/Nu mice bearing subcutaneous SB01-VR xenografts; four groups, 10 randomized mice/group. [3]

The combination, but neither single agent, significantly reduced tumor growth versus vehicle during the reported days 7–16 comparison interval. Animals were randomized to similar starting mean tumor sizes; treatments were not blinded. Early ulceration-related euthanasia in control/trametinib groups limits late comparisons.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caliper-measured xenograft tumor growthReported P value versus vehicle Combination: P = 0.0159 during days 7–16 (Mann–Whitney test). Neither single agent significantly reduced growth versus control in this reported comparison.[3]

Conditions shared by the study groups

Route
Oral gavage
Treatment course
21 consecutive days planned; some control/trametinib mice euthanized early for ulcerations.
Vehicle
0.5% methylcellulose, 5% DMSO, 0.2% Tween 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle
Vehicle only
Vehicle and both single-agent groups.Reference tumor-growth group; early ulceration-related euthanasia marked in figure.[3]
Bafetinib alone
100 mg/kg per administration; total 200 mg/kg/day
Vehicle and both single-agent groups.Did not significantly reduce tumor growth relative to control over the reported days 7–16 comparison interval.[3]
Trametinib alone
0.1 mg/kg per administration
Vehicle and both single-agent groups.Did not significantly reduce tumor growth relative to control over the reported days 7–16 comparison interval; early euthanasia for ulcerations noted.[3]
Bafetinib plus trametinib
Morning: bafetinib 100 mg/kg plus trametinib 0.1 mg/kg; evening: bafetinib 100 mg/kg
Vehicle and both single-agent groups.Combination significantly reduced tumor growth versus control during days 7–16 of the 21-day dosing period (P = 0.0159, Mann–Whitney test, as reported in Results).[3]
Vehicle
Model: SB01-VR subcutaneous xenografts in female Nu/Nu mice; 10 mice randomized per group.
Frequency: Twice daily
Reported limits: Starting age 4 weeks at purchase. Actual per-timepoint n after early euthanasia is not specified in the selected caption.
Bafetinib alone
Model: SB01-VR subcutaneous xenografts in female Nu/Nu mice; 10 mice randomized per group.
Frequency: Twice daily
Reported limits: Starting age 4 weeks at purchase. Actual per-timepoint n after early euthanasia is not specified in the selected caption.
Trametinib alone
Model: SB01-VR subcutaneous xenografts in female Nu/Nu mice; 10 mice randomized per group.
Frequency: Once daily
Reported limits: Starting age 4 weeks at purchase. Actual per-timepoint n after early euthanasia is not specified in the selected caption.
Bafetinib plus trametinib
Model: SB01-VR subcutaneous xenografts in female Nu/Nu mice; 10 mice randomized per group.
Frequency: Bafetinib twice daily; trametinib once daily
Reported limits: Starting age 4 weeks at purchase. Actual per-timepoint n after early euthanasia is not specified in the selected caption.
Methods and source locations

Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib

Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.

Fig. 6d and caption; combination Results paragraph; Methods: In Vivo

Caliper-measured xenograft tumor growth: Tumors measured three times weekly; plotted ± SEM. No exact tumor-volume values inferred from curves. — Fig. 6d and caption; combination Results paragraph; Methods: In Vivo

Vehicle · Fig. 6d and caption; combination Results paragraph; Methods: In Vivo

Bafetinib alone · Fig. 6d and caption; combination Results paragraph; Methods: In Vivo

Trametinib alone · Fig. 6d and caption; combination Results paragraph; Methods: In Vivo

Bafetinib plus trametinib · Fig. 6d and caption; combination Results paragraph; Methods: In Vivo

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 859212-16-1
Applications Bcr-Abl inhibitor
Formula C30H31F3N8O
Molecular Weight 576.6
Synonyms NS-187; INNO-406
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 92 mg/mL (159.55 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
0.5% methylcellulose+0.2% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bafetinib (INNO-406) Research References

  1. [1] Magdalena Winiarska, Kamil Bojarczuk, Beata Pyrzynska, et al. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies mAbs (2014). PMID: 25517315 DOI: 10.4161/mabs.32106 Source material
  2. [2] Andrea Haerzschel, Julie Catusse, Evelyn Hutterer, et al. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia Annals of hematology (2016). PMID: 27542958 DOI: 10.1007/s00277-016-2788-6 Source material
  3. [3] Shelli M Morris, Andrew J Mhyre, Savanna S Carmack, et al. A modified gene trap approach for improved high-throughput cancer drug discovery Oncogene (2018). PMID: 29717260 DOI: 10.1038/s41388-018-0274-4 Source material

Publications

5 publications citing this product

  1. Yusuke Kimata, .et al. , Life Sci Alliance, 2023, Feb 27;6(5):e202201657 PMID: 36849250
  2. Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
  3. S. Dallari, .et al. , Nat Commun, 2017, 8: 14830 PMID: 28368000
  4. Andrea Haerzschel, .et al. , Ann Hematol, 2016, 95(12): 1979-1988 PMID: 27542958
  5. Magdalena Winiarska, .et al. , MAbs., 2014, 6(5): 1300-1313 PMID: 25517315

Added to your cart

View Cart Checkout
Loading...